January 3, 2017 | Israeli flu vaccine developer BiondVax Pharmaceuticals Ltd. has announced that Angels High Tech Investments Ltd. has agreed to invest NIS 10.9 million (approximately $2.83 million) in the company in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange (equivalent to 844,000 Nasadq listed ADS) at the December 29, 2016 […]

With the newest patent approvals, the company says it can now enter into wide-scale development programs with pharmaceutical companies and governments.

Flu vaccinations ahead of the winter have become popular, but they do not protect against the potentially deadly bird flu, which mutates frequently and grows resistant to treatment. Israeli company BiondVax has developed a universal vaccine that could eradicate the flu.